-
Mashup Score: 4Camlipixant in Refractory Chronic Cough: A Phase 2a, Randomized Controlled Trial (RELIEF) - 13 day(s) ago
“.” American Journal of Respiratory and Critical Care Medicine, 211(6), pp. 1072–1075 Correspondence and requests for reprints should be addressed to Jaclyn A. Smith, M.B. Ch.B., F.R.C.P., Ph.D., Second Floor Education and Research Centre, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK. Email: [email protected]. Supported by Bellus Health, a GSK company (Bellus Health NCT03979638), the National Institute for Health Research (NIHR) Manchester Clinical Research Facility, and the NIHR-Wellcome
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 3Adjustable Septal Buttons for the Management of Benign Acquired Tracheoesophageal Fistulas (with Video) - 13 day(s) ago
“.” Annals of the American Thoracic Society, 22(6), pp. 934–937 Correspondence and requests for reprints should be addressed to Alma V. Burbano, M.D., Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114. E-mail: [email protected]. This article has a data supplement, which is accessible at the Supplements tab. Artificial Intelligence Disclaimer: No artificial intelligence tools were used in writing this manuscript. Not Yet Registered? Benefits
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Adjustable Septal Buttons for the Management of Benign Acquired Tracheoesophageal Fistulas TEF management requires a multidisciplinary approach. Silicone septal buttons offer a minimally invasive treatment alternative @almavbe_ @BIDMCSurgery 🔗https://t.co/wmnEJbGRfA https://t.co/2lQjts9tcu
-
-
Mashup Score: 10Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE) - 13 day(s) ago
Rationale: There is no broadly accessible treatment for patients with refractory chronic cough, a disease characterized by chronic cough that persists despite treatment for other cough-related etio…
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE) @atscommunity 🔓Open Access 🔗https://t.co/E51Ccmv5BT https://t.co/Ff8jk0YLUR
-
-
Mashup Score: 2
Rationale: It is unclear whether carriers of pathogenic variants in PAH-associated genes have a distinct response to PAH treatment. Objectives: To evaluate the effect of genetic variant status on t…
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR) @atscommunity #PAH 🔗https://t.co/oCExpodQqN https://t.co/bdVOHvbZdi
-
-
Mashup Score: 0
Rationale: Randomized controlled trials (RCTs) of lung cancer (LC) screening (LCS) using computed tomography (CT) documented LC mortality reductions between 7.2% and 29.2%, compared with a chest ra…
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Why Women Appear to Have Better Outcomes When Undergoing Screening for Lung Cancer This study explored why women appear to have been outcomes than men when screened for lung cancer @atscommunity #LungCancer 🔗https://t.co/7TUWQ1JPWY https://t.co/2I15dhh0UU
-
-
Mashup Score: 2
Rationale: It is unclear whether carriers of pathogenic variants in PAH-associated genes have a distinct response to PAH treatment. Objectives: To evaluate the effect of genetic variant status on t…
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR) @atscommunity #PAH 🔗https://t.co/oCExpodQqN https://t.co/bdVOHvbZdi
-
-
Mashup Score: 0Do Differences in Comorbidity Explain Sex-based Differences in Lung Cancer Screening Outcomes? - 15 day(s) ago
“.” Annals of the American Thoracic Society, 22(6), pp. 824–825 Artificial Intelligence Disclaimer: No artificial intelligence tools were used in writing this manuscript.
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Do Differences in Comorbidity Explain Sex-based Differences in Lung Cancer Screening Outcomes? @atscommunity #LungCancer 🔓Open Access 🔗https://t.co/Dbx2pOjEdA
-
-
Mashup Score: 1Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment Response - 15 day(s) ago
“.” American Journal of Respiratory and Critical Care Medicine, 211(6), pp. 906–907 Artificial Intelligence Disclaimer: No artificial intelligence tools were used in writing this manuscript. Not Yet Registered? Bene fits of Registration Include: • A Unique User Profile that will allow you to manage your current subscriptions (including online
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment Response @atscommunity #PAH 🔓Open Access 🔗https://t.co/PFoYNsgjR3
-
-
Mashup Score: 2Increased Pulmonary GM-CSF Causes Alveolar Macrophage Accumulation. Mechanistic Implications for Desquamative Interstitial Pneumonitis - 15 day(s) ago
Mutations in the TSC (tuberous sclerosis complex) genes result in the hyperactivation of the mTORC1 (mechanistic/mammalian target of rapamycin 1) growth pathway in mesenchymal pulmonary cells. Rapa…
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
The Bi-steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in Lymphangioleiomyomatosis @atscommunity 🔗https://t.co/gwQ7CeCyGP https://t.co/RCpc3OSCI1
-
-
Mashup Score: 10Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study - 16 day(s) ago
Rationale: Imatinib, 400 mg daily, reduces pulmonary vascular resistance and improves exercise capacity in patients with pulmonary arterial hypertension. Concerns about safety and tolerability limi…
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet-
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study @atscommunity #PAH 🔓Open Access 🔗https://t.co/DwJvUQmRB5 https://t.co/uMRSOM6tl8
-
Camlipixant in Refractory Chronic Cough: A Phase 2a, Randomized Controlled Trial (RELIEF) @atscommunity 🔓Open Access 🔗https://t.co/8rNVD1m9lh https://t.co/U9lcjObNuz